EBE – the European Trade Association representing biopharmaceutical companies of all sizes.
About EBE
10 Oct 2017

EBE and EFPIA call on the EU Commission and Member States to improve transparency on Hospital Exemptions for Advanced Therapies

“Therapies for the future - Exploring solutions for innovative treatments in Europe” will take place at the European Parliament  on 11 October 2017. In advance of this significant discussion...

Read more
27 Sep 2017

ARM, EBE, EFPIA and EuropaBio jointly publish a series of proposals to streamline requirements and accelerate approvals of clinical trials with new therapies that consist of or contain Genetically Modified Organisms (GMOs) in Europe

The Alliance for Regenerative Medicine (ARM), the European Biopharmaceutical Enterprises (EBE), the European Federation of Pharmaceutical Industries and Associations (EFPIA) and EuropaBio jointly publish a series of proposals to streamline requirements and accelerate approvals of clinical trials with new therapies that consist of or contain Genetically Modified Organisms (GMOs) in Europe....

Read more
29 Jun 2017

EFPIA, EBE and Vaccines Europe Back EU Leadership in Sustainable, Collaborative Fight Against AMR

The launch of the European Commission’s Action Plan on Antimicrobial Resistance (AMR) confirms the EU’s determination to take a leading role in combatting this phenomenon, by proposing concrete and innovative solutions to benefit patients worldwide....

Read more
10 Oct 2017

EBE and EFPIA call on the EU Commission and Member States to improve transparency on Hospital Exemptions for Advanced Therapies

“Therapies for the future - Exploring solutions for innovative treatments in Europe” will take place at the European Parliament  on 11 October 2017. In advance of this significant discussion...

Read more
27 Sep 2017

ARM, EBE, EFPIA and EuropaBio jointly publish a series of proposals to streamline requirements and accelerate approvals of clinical trials with new therapies that consist of or contain Genetically Modified Organisms (GMOs) in Europe

The Alliance for Regenerative Medicine (ARM), the European Biopharmaceutical Enterprises (EBE), the European Federation of Pharmaceutical Industries and Associations (EFPIA) and EuropaBio jointly publish a series of proposals to streamline requirements and accelerate approvals of clinical trials with new therapies that consist of or contain Genetically Modified Organisms (GMOs) in Europe....

Read more
18 Sep 2017

EBE-EFPIA Set Out Policy Positions in Their Personalised Medicines Manifesto

The EBE-EFPIA Personalised Medicine Working Group have developed a Manifesto that aims to highlight policy elements that are considered essential to ensure that personalised medicines and their paired diagnostic tests, also called companion diagnostics, successfully reach patients....

Read more
18 Oct 2017

Incentives, IP and smaller companies – the story of CureVac

How CureVac helps to change patients’ lives CureVac, a biopharmaceutical company headquartered in Tübingen, Germany, has grown from three original founders in 2000 to a mid-size company of abou...

Read more
01 Oct 2017

Eduardo Bravo discusses the importance of pharmaceutical incentives to SMEs in the Parliament Magazine

An article written by Eduardo Bravo, CEO TiGenix and EBE President on 28 September 2017, and published in the Parliament Magazine  Incentives, particularly intellectual property (IP) protection,...

Read more
28 Aug 2017

Escher “Pharmacovigilance of Biologics” Project – Outcome

The 2015 Escher project ‘Pharmacovigilance of Biologics’ investigated how adverse reactions to biologic medicines are recorded in different settings in the Netherlands, aiming to understand ho...

Read more

From Twitter

Research breakthroughs happen more easily when information is shared, writes @IMI_JU's Pierre Meulien https://t.co/gxp0RUZv12 #EHFG2017

#WeWontRest until #patients are 100% implicated in everything we do https://t.co/qKGjXrL8yV @IpsenGroup

Changes in policy/academic culture needed to steer KPIs from publications to action on patient-identified research priorities. #IMISF2017

Follow us